There is a significant development concerning semaglutide drugs like Ozempic linked to vision loss and blindness:
The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease.
The studies published earlier this week had found Ozempic significantly increases the risk of type 2 diabetes patients developing NAION (non-arteritic anterior ischemic optic neuropathy), more than doubling the likelihood. [emphasis added]
This comes from the December 18, 2024, Reuters news report, “Novo Nordisk’s Ozempic faces EU review for potential eye disease connection”.
How this new investigation of Ozempic linked to vision loss by the European Committee for the Evaluation of Adverse Reactions, or PRAC, came about is explained by this December 16, 2024, Bloomberg article, “Ozempic Blinding Link in Study Prompts Agency to Seek Probe”:
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between Novo Nordisk A/S’s blockbuster shot Ozempic and a rare form of vision loss…
A pair of large studies from the University of Southern Denmark “strengthen the suspicion” of a link between Ozempic and the rare eye condition, called NAION, the agency said.
Conducted independently, the studies both found that people who took Ozempic faced more than twice the risk of the eye condition, which can cause blindness. Both appear to confirm a link first suggested earlier this year in a Harvard University study…. [emphasis added]
Besides Ozempic, this vision loss side effect is possible with Wegovy and Rybelsus because, like Ozempic, the active ingredient for these other two Novo Nordisk drugs is semaglutide. It is semaglutide specifically that has been associated with nonarteritic anterior ischemic optic neuropathy (NAION) in several medical studies to date.
People who have been diagnosed with NAION after their use of the use of Ozempic, Wegovy, or Rybelsus and experienced vision loss may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk.
We point out that NAION is sometimes referred to more simply as an “eye stroke” and, as it is a form of “optic neuropathy” (an eye disease category), NAION may be noted only as optic neuropathy in the medical records.
[Read the article in full at source]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation